Organon & Co. (OGN)
NYSE: OGN · Real-Time Price · USD
13.85
0.00 (0.00%)
Nov 4, 2026, 1:43 PM EST - Market open
Organon & Co. Employees
Organon & Co. had 10,000 employees as of December 31, 2025. The number of employees did not change compared to the previous year. That makes Organon & Co. the 3,334th largest employer in the world and 759th in the United States.
Employees
10,000
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$609,900
Profits / Employee
$21,300
Market Cap
3.64B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 10,000 | 0 | - |
| Dec 31, 2024 | 10,000 | 0 | - |
| Dec 31, 2023 | 10,000 | 0 | - |
| Dec 31, 2022 | 10,000 | 700 | 7.53% |
| Dec 31, 2021 | 9,300 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 95,100 |
| Pfizer | 75,000 |
| Sanofi | 74,846 |
| GSK plc | 66,841 |
| Novo Nordisk | 66,700 |
| Bristol-Myers Squibb Company | 32,500 |
| Amgen | 31,500 |
| Grifols | 25,000 |
OGN News
- 5 days ago - Organon Announces Quarterly Dividend - Business Wire
- 5 days ago - Organon & Co. Quarterly report: Q3 2026 - Filings
- 16 days ago - Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing - Business Wire
- 19 days ago - Organon to present interim Phase 3 study results for MIUDELLA - TheFly
- 19 days ago - Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting - Business Wire
- 4 weeks ago - Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference - Business Wire
- 7 weeks ago - Organon announces U.S. FDA accepted for review Sebela’s sNDA for Miudella - TheFly
- 7 weeks ago - Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine Device - Business Wire